Vaughan Nelson Investment Management L.P. Purchases Shares of 264,360 Eli Lilly and Company $LLY

Vaughan Nelson Investment Management L.P. purchased a new position in Eli Lilly and Company (NYSE:LLY) in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 264,360 shares of the company’s stock, valued at approximately $201,707,000. Eli Lilly and Company makes up 1.8% of Vaughan Nelson Investment Management L.P.’s holdings, making the stock its 11th biggest position.

A number of other large investors have also recently made changes to their positions in the stock. Laurel Wealth Advisors LLC raised its stake in Eli Lilly and Company by 78,621.2% during the 2nd quarter. Laurel Wealth Advisors LLC now owns 11,552,336 shares of the company’s stock worth $9,005,392,000 after acquiring an additional 11,537,661 shares during the period. Norges Bank purchased a new stake in shares of Eli Lilly and Company in the second quarter worth $8,827,714,000. Vanguard Group Inc. raised its position in shares of Eli Lilly and Company by 1.5% during the 2nd quarter. Vanguard Group Inc. now owns 80,407,430 shares of the company’s stock valued at $62,680,004,000 after purchasing an additional 1,183,038 shares during the period. Assenagon Asset Management S.A. lifted its stake in shares of Eli Lilly and Company by 106.8% during the 2nd quarter. Assenagon Asset Management S.A. now owns 1,481,031 shares of the company’s stock valued at $1,154,508,000 after buying an additional 765,010 shares in the last quarter. Finally, Franklin Resources Inc. boosted its holdings in Eli Lilly and Company by 13.4% in the 2nd quarter. Franklin Resources Inc. now owns 4,766,865 shares of the company’s stock worth $3,715,913,000 after buying an additional 564,736 shares during the period. 82.53% of the stock is owned by hedge funds and other institutional investors.

Eli Lilly and Company Stock Up 4.1%

Shares of LLY opened at $1,107.54 on Thursday. The company has a debt-to-equity ratio of 1.71, a current ratio of 1.55 and a quick ratio of 1.24. The stock has a market capitalization of $1.05 trillion, a price-to-earnings ratio of 54.18, a price-to-earnings-growth ratio of 0.77 and a beta of 0.35. Eli Lilly and Company has a 1 year low of $623.78 and a 1 year high of $1,117.66. The business’s 50 day simple moving average is $1,028.26 and its 200-day simple moving average is $856.98.

Eli Lilly and Company (NYSE:LLY) last announced its quarterly earnings results on Thursday, October 30th. The company reported $7.02 earnings per share for the quarter, topping the consensus estimate of $6.42 by $0.60. The company had revenue of $17.60 billion for the quarter, compared to analysts’ expectations of $16.09 billion. Eli Lilly and Company had a net margin of 30.99% and a return on equity of 109.52%. Eli Lilly and Company’s quarterly revenue was up 53.9% on a year-over-year basis. During the same quarter in the previous year, the business posted $1.18 earnings per share. Eli Lilly and Company has set its FY 2025 guidance at 23.000-23.700 EPS. As a group, equities analysts expect that Eli Lilly and Company will post 23.48 earnings per share for the current fiscal year.

Eli Lilly and Company Increases Dividend

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, March 10th. Stockholders of record on Friday, February 13th will be issued a $1.73 dividend. This is a boost from Eli Lilly and Company’s previous quarterly dividend of $1.50. The ex-dividend date is Friday, February 13th. This represents a $6.92 dividend on an annualized basis and a dividend yield of 0.6%. Eli Lilly and Company’s payout ratio is presently 33.86%.

More Eli Lilly and Company News

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Lilly confirmed it will buy Ventyx Biosciences in an all-cash deal worth about $1.2 billion, gaining a pipeline of oral small-molecule NLRP3 inhibitors and inflammatory disease candidates that expand Lilly beyond diabetes/weight-loss. This acquisition is a clear pipeline/strategic positive. Eli Lilly to buy Ventyx Biosciences in $1.2 billion deal
• Positive Sentiment: Lilly expanded its obesity/metabolic pipeline via a multiyear partnership/licensing deal with Nimbus (reported value ~$1.3B), adding an oral obesity candidate to its development portfolio — another growth pathway beyond injectables. Boston biotech Nimbus to partner with Eli Lilly on weight-loss pill in $1.3 billion deal
• Positive Sentiment: Lilly struck a collaboration with InduPro on a next-gen cancer program worth up to $950 million, strengthening oncology exposure and long-term revenue optionality. Lilly links up with InduPro in next-gen cancer treatment deal worth up to $950M
• Positive Sentiment: Clarivate named several Lilly cardiometabolic launches among drugs to watch for 2026, highlighting continued product catalysts beyond current blockbusters. Lilly’s prospective cardiometabolic launches dominate list of drugs to watch in 2026: Clarivate
• Positive Sentiment: Analysts are bullish: Citigroup flagged ~50% upside, and several upgrades/positive notes have circulated, supporting momentum and investor confidence in Lilly’s pipeline and earnings outlook. Eli Lilly Stock (LLY) Has 50% Upside, Says Citigroup
• Neutral Sentiment: The stock printed an all-time high intraday as buyers priced in the M&A and deal flow; that’s market confirmation of the reaction but not a new fundamental. Eli Lilly stock hits all-time high of 1113.03 USD
• Negative Sentiment: Lilly faces legal pressure: the Indiana attorney general sued alleging inflated insulin pricing, a regulatory and reputational overhang that could lead to fines, settlements or policy scrutiny. Indiana sues Eli Lilly alleging insulin price-fixing scheme

Wall Street Analysts Forecast Growth

A number of equities research analysts have commented on LLY shares. Sanford C. Bernstein reissued an “outperform” rating on shares of Eli Lilly and Company in a report on Friday, December 19th. UBS Group began coverage on Eli Lilly and Company in a research note on Tuesday. They set a “buy” rating and a $1,250.00 target price on the stock. HSBC reissued a “hold” rating and issued a $1,070.00 price target on shares of Eli Lilly and Company in a report on Wednesday, December 10th. Wells Fargo & Company increased their price objective on shares of Eli Lilly and Company from $1,100.00 to $1,200.00 and gave the company an “overweight” rating in a report on Wednesday, December 10th. Finally, National Bankshares set a $1,286.00 target price on shares of Eli Lilly and Company in a report on Monday, December 1st. Five analysts have rated the stock with a Strong Buy rating, eighteen have issued a Buy rating and four have issued a Hold rating to the company. According to MarketBeat, the stock currently has an average rating of “Buy” and a consensus target price of $1,169.00.

Eli Lilly and Company Profile

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.